The number of nephrons in different glomerular diseases

Davide Viggiano1,*, Michelangelo Nigro2,*, Francesco Sessa3,4, Graziano Vignolini3,4, Riccardo Campi3,4, Sergio Serni3,4, Rosa Maria Pollastro5, Gianfranco Vallone6, Giuseppe Gigliotti2 and Giovambattista Capasso5,7

1 Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy
2 UOC of Nephrology and dialysis, Eboli Hospital “Maria SS Addolorata”, Eboli, Italy
3 Department of Urologic Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy
4 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
5 Department of Translational Medicine, University of Campania “L. Vanvitelli”, Naples, Italy
6 Department of Radiology, University of Naples “Federico II”, Naples, Italy
7 Biogem, Ariano Irpino, Italy
* These authors contributed equally to this work.

ABSTRACT

Background: The total number of nephrons has been measured mainly from post-mortem studies and only in selected populations. Data from living subjects are scanty, and direct comparisons among different glomerular diseases are lacking. The present work exploits modern methodology to estimate the total nephron number in glomerulopathies with prevalent proteinuria/nephrotic syndrome versus glomerulopathies with nephritic syndrome (IgA nephropathy (IgAN), lupus nephritis), thus extending previous observations about the number and function of glomeruli in different physiological and pathological states.

Methods: This is a retrospective study based on one hundred and seven patients who have undergone renal biopsy. The glomerular density has been estimated from the biopsy specimens and the total cortical volume has been obtained from ultrasound recordings. Stereological methods have been applied to calculate the total number of nephrons and their volume. The correlation between clinical parameters and quantitative morphological data have studied using the Pearson correlation coefficient (r).

Results: The total number of nephrons inversely correlated with the systolic blood pressure (r = −0.4, p < 0.05). In proteinuric diseases, such as focal segmental glomerulo-sclerosis (FSGS), membranous nephropathy (MN) and diabetes, the change in estimated GFR (eGFR) directly correlated with the total number of non-sclerotic glomeruli (NSG) (r = 0.62, p < 0.01), whereas in nephritic syndrome no significant correlation was observed. The alterations in eGFR occurring in nephritic syndromes such as IgAN cannot be explained on the basis of the number of NSG.

Discussion: The fusion of the podocyte foot-processes that typically occurs in purely proteinuric diseases does not modify the glomerular filtration rate: therefore in these situations, the change in eGFR depends mainly on the number of available glomeruli. On the other side, the eGFR decrease occurring in nephritic syndromes, such as IgAN, cannot be explained simply on the basis of the number of NSG and likely depends on the substantial involvement of the mesangial axis. Future studies should
verify whether these changes are reversible with appropriate therapy, thus reversing eGFR decrease.

**Subjects** Nephrology, Pathology

**Keywords** Nephron number, eGFR, Blood pressure, Nephrotic syndrome, Nephritic syndrome, IgA nephropathy, Diabetic nephropathy, Membranous nephropathy, Minimal change disease, Podocytes

**INTRODUCTION**

According to the “intact nephron hypothesis” proposed by Neal Bricker in 1960, a greater fraction of the total renal excretion must be performed by fewer, functionally intact tubules when kidney damage occurs (Bricker, Morrin & Kime, 1960; Hayman et al., 1939; Platt, 1952). However, in 1974 the work by Barry Brenner’s laboratory in animal models (Deen et al., 1974) emphasized that also the remaining glomeruli increase their filtration rate (GFR; “hyperfiltration”) and become hypertrophic. The increase in the GFR would be a maladaptive response that may damage the glomeruli (Hostetter et al., 1981). In 1986–1993, Barker proposed that an abnormal fetal environment (low-birth weight) can favor older age pathologies (e.g. coronary heart disease and hypertension) (Barker & Osmond, 1986, 1988; Barker et al., 1993). These hypotheses were then merged into the “nephron under-dosing” (Brenner, Garcia & Anderson, 1988): an inherited, low nephron endowment (e.g. in preterm infants) would lead to subclinical hyperfiltration and greater risk of hypertension in chronic kidney disease (CKD) (Brenner, Lawler & Mackenzie, 1996). The anatomical correlate of the hyperfiltration is thought to be an increase in the glomerular volume (Fogo & Ichikawa, 1991). Accordingly, in autopsy studies, a correlation between the total number of glomeruli and mean glomerular volume has been repeatedly observed (Hoy et al., 2003; Hughson et al., 2008), suggesting that a lower number of nephrons is compensated by glomerular hypertrophy. The recent data by Denic et al. (2017a) confirm these observations in vivo, as a higher single-nephron measured glomerular filtration rate is associated with larger nephrons and more glomerulosclerosis. Unfortunately, autopsy data gave contrasting information regarding a reduced number of nephrons in hypertensive subjects (Hughson et al., 2006, 2014; Kanzaki et al., 2017).

Several systemic diseases such as diabetes (Bank, 1991) and obesity (Chagnac et al., 2000) are initially accompanied by hyperfiltration, and at later stages by hypofiltration (Anastasio et al., 2017). It is unclear if this also applies to CKD (Brenner, Lawler & Mackenzie, 1996; Kanzaki et al., 2017). Accordingly, obesity and diabetes (Tsuboi et al., 2012), CKD (Kanzaki et al., 2017), minimal change disease (MCD) (Koike et al., 2011), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN) (Tsuboi et al., 2011) and IgA nephropathy (IgAN) (Tsuboi et al., 2010) lead to a reduced number of nephrons. In these pathologies the presence of larger, hypertrophic glomeruli has also been observed: hypertension, diabetes, obesity (Tsuboi et al., 2012), CKD, MCD (Fogo et al., 1990), FSGS (Nishimoto et al., 1997) and IgAN (Tóth & Takebayashi, 1998). The glomerular hypertrophy in early obesity and hypertension might, however, derive from a greater metabolic and excretory demand (Osterby & Gundersen, 1975).
Therefore, the reduction of the estimated GFR (eGFR) in kidney diseases would result in part from a reduced number of non-sclerosed glomeruli (the “chronic” part of the disease) and a possibly reversible, functional hypofiltration at the level of individual glomeruli (the “acute” part of the disease). Empiric observations have validated the relation between the number of non-sclerosed glomeruli and the eGFR (Kanzaki et al., 2017).

Several proteinuric glomerular diseases (e.g. diabetic nephropathy (DN), FSGS, MCD, amyloidosis) show damages of the podocytes in terms of loss of foot processes commonly referred to as “effacement” (Shankland, 2006) and thought to be responsible for the nephrotic syndrome. The effacement of foot process is much less evident in nephritic syndromes (with hematuria and low proteinuria) such as IgAN (van den berg et al., 2004). The different behavior of podocyte foot process in these two conditions (nephrotic/proteinuric vs nephritic syndromes) leads to speculation that the change in eGFR has different etiology in these conditions. In this work we compared the association between nephron number and eGFR in nephrotic and nephritic syndromes. In other terms, we expect that the relationship GFR-nephron number has a different slope in proteinuric syndromes compared to nephritic syndromes. Although several data are now available about the total number of nephrons, data regarding CKD patients with nephritic and nephrotic syndromes are still scanty, and this work aims at filling this knowledge gap.

**MATERIALS AND METHODS**

**Study population**

This is a retrospective, observational cross-sectional study. After Institutional Review Board approval and informed consent, data in the period 2014–2018 from patients were retrospectively collected in an a priori developed dataset. Data were taken from the clinical and immune-pathological records of the Nephrology Unit of the Eboli Hospital, the Nephrology Unit of the University of Campania “L. Vanvitelli” and the Department of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence. Written informed consent was obtained from the participants.

One hundred and seven renal biopsies were analyzed in this pilot study. The following inclusion criteria were used: (1) histological diagnosis of FSGS, MN, DN, MCD, IgMN, IgAN, Lupus nephritis; (2) age between 20 and 60 years. Furthermore, patients in the proteinuric group were excluded if proteinuria was less than 1g/24 h.

Of the initially identified 107 patients, only 59 satisfied the inclusion criteria, and were included in further analysis.

The diagnosis of the subjects derived from histological and immunofluorescence (using standard panels of antibodies) staining of tissue biopsies. Only biopsies containing at least four glomeruli were used. The minimum number of glomeruli to select reliable biopsies was based on previous evidence (Denic et al., 2017a, 2017b). In preliminary study, we found no significant correlation between the area of the section (that is the size of the biopsy sample) and the measured variables.
Kidney function and clinical characteristics
Clinical parameters (age, gender, body weight, systolic and diastolic arterial blood pressure) and hematological parameters (calibrated creatinine, blood urea nitrogen and uric acid) have been retrieved for each patient before the biopsy procedure, and the GFR was estimated using the CKD-EPI formula. Subject height was not available from clinical recordings, therefore the BMI could not be calculated and only the body weight was included in the analysis. Hypertension was defined as blood pressure $\geq 140/90$ mmHg.

Imaging
Ultrasound images in longitudinal and transversal planes were also analyzed for each patient. For each center, only one ultrasound operator acquired the kidney images. The protocol for image acquisition was the same in the three centers. Three different ultrasound devices were used in the three centers. We could not detect systematic differences in ultrasound parameters among centers. In 35 patients the kidney volume estimated by ultrasound was also compared to the kidney volume measured using the Cavalieri principle on CT scan images, confirming the absence of bias among centers in the estimate of kidney volume.

Biopsy morphology
The biopsy specimens have been fixed in Bouin, processed and embedded in paraffin using routine methods. Two and half micron-thick sections ($2.5 \mu$) were stained with hematoxylin-eosin or periodic acid schiff. The entire sections have been scanned using an Aperio CS2 scanner (Leica): the use of this system of whole slide image, allows viewing virtually the entire biopsy at high resolution (0.8 pixel per micron).

Section images have been analyzed using the ImageJ free software. The total number of glomeruli, the number of non-sclerotic glomeruli (NSG) per unit area of cortex ($\text{mm}^2$) was manually counted:

$$\text{ADglom}_\text{NSG} \left( \text{n/mm}^2 \right) = \frac{\text{NSG Area Density}}{\text{number of NSG/area of cortex in the specimen (mm}^2\text{)}}$$

The percent of NSG was calculated as: 100 $\times$ number of NSG/total number of glomeruli.

The area covered by each glomerulus was also measured and the proportional area of NSG ($\text{PrAglo}m_{\text{NSG}} = \text{total area of NSG/area of cortex}$) was calculated. The area considered was only the region of the histological section containing the glomeruli, excluding the medulla that could be present in the section.

Interstitial fibrosis/tubular atrophy, that is the percentage of cortical area involved by the tubular atrophy or interstitial fibrosis, was defined as follows: T0, 0–25%; T1, 26–50% and T2, >50%.

The reliability of the measurements has been tested by repeating the analysis by a second observer.
Estimation of kidney volume and parenchymal volume

The total kidney volume (including the renal sinus) was estimated from ultrasound images using the following ellipsoid-KV3 formula proposed by Higashihara et al. (2015), which had better performance than the ellipsoid formula:

$$\text{Total kidney volume} = 84 + 1.01 \times \frac{\pi}{24} \times LD \times (ML+AP)^2$$

where LD (longitudinal diameter) is the maximum axis of the kidney in longitudinal plane, ML is the medio-lateral axis and AP the antero-posterior axis, both perpendicular to LD and passing through its midpoint (see Fig. S1).

The volume of the renal sinus was also estimated using the same approach. The parenchymal volume was established as the difference between the total kidney volume and the volume of the renal sinus. The volume of the kidney cortex was then estimated using a constant cortex/parenchyma ratio of 0.7 (Denic et al., 2017a, 2017b, Wang et al., 2014).

To verify the bias of this approach, a pilot study using CT images with contrast medium from 35 patients identified the cortical volume using the Cavalieri principle; the coefficient of correlation between the true parenchymal volume and the estimate using the ellipsoid was 0.8 ($p < 0.01$). Similarly, the coefficient of correlation between the true parenchymal volume and the estimate using the ellipsoid-KV3 was 0.8 ($p < 0.01$).

Furthermore, we also estimated the cortical volume using the formula by Nakazato, Ikehira & Imasawa (2017) as previously described.

Estimated volume of the renal cortex (cm$^3$)
$$= 0.012 \times \text{renal length (cm)}^{0.92} \times \text{width (cm)}^{0.67} \times \text{body weight (kg)}^{0.40} \times \text{body height (cm)}^{0.67} \times \text{eGFR (ml/min/1.73 m}^2) \times 1.12 \text{ if diabetes.}$$

The Pearson coefficient of correlation between the cortical volume and that estimated using the Nakazato formula was 0.62 ($p < 0.01$).

Estimation of total number of nephrons

The estimate of number of nephrons per kidney follows the method reported by Denic et al. (2017a, 2017b).

Briefly, first the volume of NSG (VglomNSG) and the NSG volume density (DglomNSG, n/mm$^3$ of cortex) were estimated by the Weibel–Gomez (Weibel & Gomez, 1962) stereological model, allowing to estimate three-dimensional information (volume, counts/volume) from two-dimensional biopsy images:

$$\text{Vglom}_{\text{NSG}} = \text{NSG volume (mm}^3) = 1.382 \times (\text{Mean area of NSG})^{1.5}/1.01$$

$$\text{Dglom}_{\text{NSG}} = \text{NSG volume density (n/mm}^3)$$
$$= 0.724 \times [(\text{ADglom}_{\text{NSG}})^3/(\text{PrAgлом}_{\text{NSG}})]^{0.5}$$

The total number of nephrons per kidney was therefore:

$$\text{Ngłom}_{\text{NSG}} = \text{total number of nephrons}$$
$$= \text{Dglom}_{\text{NSG}} \times \text{cortical volume (mm}^3)/1.81$$
The correction factor 1.81 was needed to control for tissue shrinkage of histological sections and volume shrinkage of biopsy core due to loss of blood perfusion (Fulladosa et al., 2003; Lerman et al., 1990).

Statistical analysis
Statistical analyses were performed using SPSS Statistics 13 for Windows and R environment. Continuous data were summarized and presented as means ± SD. Categorical variables are presented as percentage.

Normality distribution was tested with the Shapiro–Wilk test. Since most of the variables did not satisfy the normality assumption, the Mann–Whitney U test was used in place of the t-test to compare the two groups (nephrotic vs nephritic patients). For categorical variables (gender), the chi-square statistic was used to compare the two groups.

To correlate the clinical parameters to quantitative morphological data, the Pearson’s test was calculated separately for each variable. The population size was selected in order to find a Pearson’s correlation coefficient (r) above 0.4 between clinical variables and morphological data, with a power of 80%. We defined statistical significance as p < 0.05.

RESULTS
The mean value of the parameters of the patients and the density of glomeruli are reported in Table 1. The eGFR was significantly correlated with the age (r = −0.31, p < 0.01). The total number of glomeruli was only border-line correlated to the patient’s age (r = −0.21, p = 0.06). The % globally sclerosed glomeruli was not significantly correlated with age in this population with kidney diseases (r = 0.07, p = 0.56).

When all data were pooled, the total number of nephrons inversely correlated with the systolic (SBP) blood pressure (SBP: r = −0.40, p = 0.02; diastolic blood pressure (DBP): r = −0.35, p = 0.06). This is also reported in Fig. 1A. Conversely, the volume of glomeruli (VglomNSG) did not correlate with the blood pressure (r = 0.06 and −0.04, p = 0.63 and 0.73 for SBP and DBP respectively, Fig. 1B). We then verified whether the size of glomeruli was correlated with hyperfiltration as indexed by eGFR. When pooling all data, the correlation between eGFR and VglomNSG was not significant (r = −0.08, p = 0.64). The total number of glomeruli was not correlated with the volume of glomeruli (r = −0.22, p = 0.18).

There was no significant correlation between nephron number and proteinuria (mg/24 h) (r = −0.04, p = 0.77).

Finally, higher eGFR correlated with more nephrons (r = −0.39, p = 0.02).

We therefore tested whether the correlation between the total number of glomeruli and eGFR was different in glomerulopathies accompanied by podocyte foot process effacement (nephrotic/proteinuric syndromes) and in nephritic syndromes (IgAN) (Jameson & Loscalzo, 2017). As reported in Table 1, the two syndromes showed no significant difference in the total number of NSG. However, in nephrotic/proteinuric syndromes the total number of glomeruli predicted the eGFR (r = 0.62, p = 0.003), whereas in IgAN there was no correlation between eGFR and total number of NSG (r = 0.03, p = 0.91). This is also shown in Fig. 1C. Lower eGFR also correlated with older age (r = −0.31, p < 0.01).
The total number of glomeruli was only borderline correlated with the patients age ($r = -0.21$, $p = 0.06$). The % globally sclerosed glomeruli was not significantly correlated with age in this population with kidney diseases ($r = 0.07$, $p = 0.56$).

**DISCUSSION**

The total number of nephrons has been measured mainly from post-mortem studies and only in selected populations. Data from living subjects are scanty, and direct comparisons among different glomerular diseases are lacking. The main result of the present study is that the change of eGFR in IgAN is due to a dysfunction of the glomeruli whereas in nephrotic/proteinuric syndromes it reflects the total number of glomeruli (Rauen et al., 2015, 2018). This is the first study in human subjects demonstrating this difference between the two syndromes.

The present work extends previous observations about the number and function of glomeruli in different physiological and pathological states (Tsuboi et al., 2012; Kanzaki et al., 2017; Koike et al., 2011).

---

**Table 1** Clinical data of the populations under study (data represent mean ± SEM).

|                      | Proteinuric/Nephrotic syndrome | Nephritic syndrome | $p$ (test statistics in parenthesis) |
|----------------------|-------------------------------|-------------------|---------------------------------------|
| $N$ (total = 59)     | 33 (FSGS = 14; MN = 8; DN = 4; IgMN = 2; MCD = 5) | 26 (IgAN = 21; lupus nephritis = 5) |                                        |
| Gender (F/M)         | 9/24 (27%/73%)                | 11/15 (42%/58%)   | 0.27 (Chi-square test)                |
| Age (years)          | 48 ± 13                       | 42 ± 16           | 0.06 (Mann–Whitney $U$)               |
| Body weight (Kg)     | 80 ± 18                       | 79 ± 16           | 0.99 (Mann–Whitney $U$)               |
| SBP (mmHg)           | 130 ± 15                      | 134 ± 15          | 0.15 (Mann–Whitney $U$)               |
| DBP (mmHg)           | 78 ± 9                        | 82 ± 10           | 0.18 (Mann–Whitney $U$)               |
| Prevalence of hypertension | 34%                  | 50%               | 0.38 (Chi-square test)                |
| Urea (mg/dl)         | 71 ± 33                       | 60 ± 43           | 0.08 (Mann–Whitney $U$)               |
| Creatinine (mg/dl)   | 1.8 ± 1.0                     | 1.5 ± 1.3         | 0.10 (Mann–Whitney $U$)               |
| Uric acid (mg/dl)    | 6 ± 1.6                       | 5.9 ± 2.0         | 0.84 (Mann–Whitney $U$)               |
| Proteinuria (mg/24 h)| 4,248 ± 3,085                 | 1,340 ± 1,362     | <0.01 (Mann–Whitney $U$)              |
| Estimated glomerular filtration rate (ml/min/1.73 m$^2$) | 56 ± 34                     | 74 ± 35           | 0.06 (Mann–Whitney $U$)               |
| TA/IF score (T0/T1/T2)| 42%/38%/19%                 | 68%/31%/0%        | 0.08 (Chi-square)                     |
| Kidney length (mm)   | 109 ± 11                      | 106 ± 10          | 0.25 (Mann–Whitney $U$)               |
| Total kidney volume (ml) | 265 ± 53               | 231 ± 48          | 0.01 (Mann–Whitney $U$)               |
| Kidney parenchyma volume (ml) | 155 ± 41             | 129 ± 40          | 0.02 (Mann–Whitney $U$)               |
| Kidney cortical volume (ml) | 108 ± 29              | 90 ± 27           | 0.02 (Mann–Whitney $U$)               |
| Kidney cortical volume (Nakazato formula; ml) | 121 ± 45            | 118 ± 29          | 0.83 (Mann–Whitney $U$)               |
| % Sclerotic glomeruli| 13 ± 17                       | 7 ± 11            | 0.20 (Mann–Whitney $U$)               |
| Vglo$\text{m}_{\text{NSG}}$ (mm$^3 \times 10^{-6}$) | 6 ± 3.2              | 4.6 ± 2.5         | 0.05 (Mann–Whitney $U$)               |
| Nglom$\text{m}_{\text{NSG}}$ ($\times 1,000$) | 589 ± 288             | 619 ± 311         | 0.80 (Mann–Whitney $U$)               |
| Nglom$\text{m}_{\text{NSG}}$ ($\times 1,000$) using Nakazato formula for cortical volume | 667 ± 345            | 795 ± 361         | 0.23 (Mann–Whitney $U$)               |

Note: FSGS, focal segmental glomerulosclerosis; MN, membranous nephropathy; DN, diabetic nephropathy; IgMN, IgM nephropathy; MCD, minimal change disease; IgAN, IgA nephropathy; IF/TA, interstitial fibrosis/tubular atrophy; SBP/DBP, systolic/diastolic blood pressure.
Figure 1 Relationship between total number of nephrons, arterial blood pressure and eGFR. (A) Relationship between total number of nephrons and systolic (SBP, filled circles) and diastolic (DBP, empty circles) blood pressures. (B) Relationship between glomerular volume and systolic (SBP, filled circles) and diastolic (DBP, empty circles) blood pressures. (C–D) Relationship between total number of nephrons and the total eGFR. Only nephrotic/proteinuric syndromes show significant correlation, whereas in nephritic syndromes the two variables are not correlated.
The total number of nephrons (NglomerNSG) was inversely correlated with the systolic and diastolic blood pressure. This result is consistent with previous reports of a lower number of nephrons in subjects with increased blood pressure (Keller et al., 2003; Kanzaki et al., 2017).

However, the number of nephrons did not correlate with the glomerular volume, in contrast to previous findings (Tsuboi et al., 2010).

The total number of glomeruli predicted the eGFR, as suggested by Kanzaki et al. (2017). However, subgroup analysis revealed that this was true mostly for proteinuric patients. This was consistent with our previous finding that glomerular density correlated with eGFR only in specific subpopulations and not in all glomerular diseases (Nigro et al., 2018). This is consistent also with the hypothesis that the eGFR does not reflect simply the number of nephrons, but also their mean activity, that is GFR depends not only on anatomical but also on functional changes.

Therefore, we believe that the CKD staging does not appropriately reflect the fact that in some diseases a specific stage reflects anatomical changes, whereas in others it may reflect a functional (possibly reversible) problem (Viggiano et al., 2019).

The study explores for the first time the number of nephrons and glomerular volume in different glomerular diseases in vivo. The data are in agreement with previous observations, thus suggesting that major faults in the methodology are not present and that the collateral conclusions of the work are likely correct. Furthermore, it is a multicenter study (Eboli, Naples and Florence). Despite its novelty, our study is not devoid of limitations. First, this is a preliminary experience with small sample size. As such, we could not formally compare the outcomes. Second, ultrasound and other imaging modalities often do not allow for a precise estimate of the kidney cortex, as the cortico-medullary differentiation is very often absent in images. Therefore, our study, in line with other studies, has used a constant cortex-parenchyma ratio. This may lead to a systematic bias (if the ratio is biased). Furthermore, it is far to be proven that the cortex-parenchyma ratio is constant at different eGFR levels: this may have led to further distortion of the total number of nephrons. However, our conclusions are robust even when using the Nakazato formula to estimate the renal cortex, which is not dependent upon an assumption of a constant cortex-parenchyma ratio. Finally, we have used the eGFR formula (CKD-EPI) throughout the analysis. However, the coefficient of variation of the formula greatly increases as the eGFR increases and is very noisy at GFR above 60 ml/min/1.73 m² (though unbiased). Notwithstanding these limitations, the estimate of the total number of nephrons is not very difficult and might become part of routine clinical practice if appropriate measures are routinely presented by the pathologist and the radiologist/ultrasound technician.

To these aims, adequately powered trials with longer follow-up are needed. Overall, larger studies are needed to confirm these findings and to its indications and limits.

**CONCLUSIONS**

Our data show that in proteinuric diseases the total number of nephrons accounts for most of the variability of eGFR in proteinuric diseases. Therefore, the fusion of the podocyte
foot-processes does not modify the glomerular filtration rate. Conversely, in nephritic syndromes the total number of nephrons does not explain the modifications of eGFR. Therefore, in nephritic syndromes the change of eGFR likely depends on the substantial involvement of the mesangial axis. Future studies should verify whether these changes are reversible with appropriate therapy, thus leading to improved eGFR.

**ADDITIONAL INFORMATION AND DECLARATIONS**

**Funding**
The authors received no funding for this work.

**Competing Interests**
The authors declare that they have no competing interests.

**Author Contributions**
- Davide Viggiano conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
- Michelangelo Nigro conceived and designed the experiments, performed the experiments, contributed reagents/materials/analysis tools, approved the final draft.
- Francesco Sessa performed the experiments, authored or reviewed drafts of the paper, approved the final draft.
- Graziano Vignolini performed the experiments, approved the final draft.
- Riccardo Campi performed the experiments, approved the final draft.
- Sergio Serni performed the experiments, approved the final draft.
- Rosa Maria Pollastro performed the experiments, approved the final draft.
- Gianfranco Vallone performed the experiments, authored or reviewed drafts of the paper.
- Giuseppe Gigliotti conceived and designed the experiments, contributed reagents/materials/analysis tools, approved the final draft.
- Giovambattista Capasso conceived and designed the experiments, contributed reagents/materials/analysis tools, authored or reviewed drafts of the paper, approved the final draft.

**Human Ethics**
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The ASL Napoli 3 Ethics Committee approved this retrospective study (Ethical Application Ref: n. 59_r.p.s.o.).

**Data Availability**
The following information was supplied regarding data availability:

The raw measurements are available in the Supplemental File.
Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.7640#supplemental-information.

REFERENCES
Anastasio P, Viggiano D, Zacchia M, Altobelli C, Capasso G, Gaspare De Santo N. 2017. Delay in renal hemodynamic response to a meat meal in severe obesity. *Nephron* 136(2):151–157 DOI 10.1159/000453283.

Bank N. 1991. Mechanisms of diabetic hyperfiltration. *Kidney International* 40(4):792–807 DOI 10.1038/ki.1991.277.

Barker DJ, Osmond C. 1986. Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales. *Lancet* 1(8489):1077–1081 DOI 10.1016/0140-6736(86)91340-1.

Barker DJ, Osmond C. 1988. Low birth weight and hypertension. *BMJ* 297(6641):134–135 DOI 10.1136/bmj.297.6641.134-b.

Barker DJ, Osmond C, Simmonds SJ, Wield GA. 1993. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. *British Medical Journal* 306(6875):422–426 DOI 10.1136/bmj.306.6875.422.

Brenner BM, Garcia DL, Anderson S. 1988. Glomeruli and blood pressure: less of one, more the other? *American Journal of Hypertension* 1988(4):335–347 DOI 10.1093/ajh/1.4.335.

Brenner BM, Lawler EV, Mackenzie HS. 1996. The hyperfiltration theory: a paradigm shift in nephrology. *Kidney International* 49(6):1774–1777 DOI 10.1038/ki.1996.265.

Bricker NS, Morrin PA, Kime SW Jr. 1960. The pathologic physiology of chronic Bright’s disease. An exposition of the “intact nephron hypothesis”. *American Journal of Medicine* 28(1):77–98 DOI 10.1016/0002-9343(60)90225-4.

Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. 2000. Glomerular hemodynamics in severe obesity. *American Journal of Physiology* 278(5):F817–F822 DOI 10.1152/ajprenal.2000.278.5.F817.

Deen WM, Maddox DA, Robertson CR, Brenner BM. 1974. Dynamics of glomerular ultrafiltration in the rat. VII: response to reduced renal mass. *American Journal of Physiology* 227(3):556–562 DOI 10.1152/ajplegacy.1974.227.3.556.

Denic A, Lieske JC, Chakkera HA, Poggio ED, Alexander MP, Singh P, Kremers WK, Lerman LO, Rule AD. 2017a. The substantial loss of nephrons in healthy human kidneys with aging. *Journal of the American Society of Nephrology* 28(1):313–320 DOI 10.1681/ASN.2016020154.

Denic A, Mathew J, Lerman LO, Lieske JC, Larson JJ, Alexander MP, Poggio E, Glassock RJ, Rule AD. 2017b. Single-nephron glomerular filtration rate in healthy adults. *New England Journal of Medicine* 376(24):2349–2357 DOI 10.1056/NEJMa1614329.

Fogo A, Hawkins EP, Berry PL, Glick AD, Chiang ML, MacDonell RC Jr, Ichikawa I. 1990. Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. *Kidney International* 38(1):115–123 DOI 10.1038/ki.1990.175.

Fogo A, Ichikawa I. 1991. Evidence for a pathogenic linkage between glomerular hypertrophy and sclerosis. *American Journal of Kidney Diseases* 17:666–669 DOI 10.1016/S0272-6386(12)80347-7.

Fulladosa X, Moreso F, Narváez JA, Grinyó JM, Serón D. 2003. Estimation of total glomerular number in stable renal transplants. *Journal of the American Society of Nephrology* 14(10):2662–2668 DOI 10.1097/01.ASN.0000088025.33462.B0.
Hayman JM Jr, Shumway NP, Dumke P, Miller M. 1939. Experimental hyposthenuria. *Journal of Clinical Investigation* **18**(2):195–212 DOI 10.1172/JCI101035.

Higashihara E, Nutahara K, Okegawa T, Tanbo M, Hara H, Miyazaki I, Kobayasi K, Nitatori T. 2015. Kidney volume estimations with ellipsoid equations by magnetic resonance imaging in autosomal dominant polycystic kidney disease. *Nephron* **129**(4):253–262 DOI 10.1159/000381476.

Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. 1981. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. *American Journal of Physiology* **241**(1):F85—F93 DOI 10.1152/ajprenal.1981.241.1.F85.

Hoy WE, Douglas-Denton RN, Hughson MD, Cass A, Johnson K, Bertram JF. 2003. A stereological study of glomerular number and volume: preliminary findings in a multiracial study of kidneys at autopsy. *Kidney International Supplements* **63**(83):S31–S37 DOI 10.1046/j.1523-1755.63.s83.8.x.

Hughson MD, Douglas-Denton R, Bertram JF, Hoy WE. 2006. Hypertension, glomerular number, and birth weight in African Americans and white subjects in the southeastern United States. *Kidney International* **69**(4):671–678 DOI 10.1038/sj.ki.5000401.

Hughson MD, Gobe GC, Hoy WE, Manning RD Jr, Douglas-Denton R, Bertram JF. 2008. Associations of glomerular number and birth weight with clinicopathological features of African Americans and whites. *American Journal of Kidney Diseases* **52**(1):18–28 DOI 10.1053/j.ajkd.2008.03.023.

Hughson MD, Puelles VG, Hoy WE, Douglas-Denton RN, Mott SA, Bertram JF. 2014. Hypertension, glomerular hypertrophy and nephrosclerosis: the effect of race. *Nephrology Dialysis Transplantation* **29**(7):1399–1409 DOI 10.1093/ndt/gft480.

Jameson JL, Locasalo J, eds. 2017. *Harrison’s nephrology and acid-base disorders*. Third edition. New York: McGraw-Hill Education Medical.

Kanzaki G, Puelles VG, Cullen-McEwen LA, Hoy WE, Okabayashi Y, Tsuboi N, Shimizu A, Denton KM, Hughson MD, Yokoo T, Bertram JF. 2017. New insights on glomerular hyperfiltration: a Japanese autopsy study. *JCI Insight* **2**(19):94334 DOI 10.1172/jci.insight.94334.

Keller G, Zimmer G, Mall G, Ritz E, Amann K. 2003. Nephron number in patients with primary hypertension. *New England Journal of Medicine* **348**(2):101–108 DOI 10.1056/NEJMoa020549.

Koike K, Tsuboi N, Utsunomiya Y, Kawamura T, Hosoya T. 2011. Glomerular density-associated changes in clinicopathological features of minimal change nephrotic syndrome in adults. *American Journal of Nephrology* **34**(6):542–548 DOI 10.1159/000334360.

Lerman LO, Bentley MD, Bell MR, Rumberger JA, Romero JC. 1990. Quantitation of the in vivo kidney volume with cine computed tomography. *Investigative Radiology* **25**(11):1206–1211 DOI 10.1097/00004424-199011000-00009.

Nigro M, Viggiano D, Ragone V, Trabace T, di Palma A, Rossini M, Capasso G, Gesualdo L, Gigliotti G. 2018. A cross-sectional study on the relationship between hematological data and quantitative morphological indices from kidney biopsies in different glomerular diseases. *BMC Nephrology* **19**(1):62 DOI 10.1186/s12882-018-0846-0.

Nishimoto K, Shiiki H, Nishino T, Uyama H, Iwano M, Dohi K. 1997. Reversible glomerular hypertrophy in adult patients with primary focal segmental glomerulosclerosis. *Journal of The American Society of Nephrology* **8**:1668–1678.
Osterby R, Gundersen HJ. 1975. Glomerular size and structure in diabetes mellitus. I. Early abnormalities. Diabetologia 11(3):225–229 DOI 10.1007/BF00422326.

Platt R. 1952. Structural and functional adaptation in renal failure. British Medical Journal 1:1313–1318 DOI 10.1136/bmj.1.4772.1313.

Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J. 2015. Investigators intensive supportive care plus immunosuppression in IgA nephropathy. New England Journal of Medicine 373(23):2225–2236 DOI 10.1056/NEJMoai415463.

Rauen T, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J, for the STOP-IgAN Investigators. 2018. Effects of two immunosuppressive treatment protocols for IgA nephropathy. Journal of the American Society of Nephrology 29(1):317–325 DOI 10.1681/ASN.2019020150.

Shankland SJ. 2006. The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney International 69(12):2131–2147 DOI 10.1038/sj.ki.5000410.

Tóth T, Takebayashi S. 1998. Glomerular hypertrophy as a prognostic marker in childhood IgA nephropathy. Nephron 80(3):285–291 DOI 10.1159/000045188.

Tsuboi N, Kawamura T, Koike K, Okonogi H, Hirano K, Hamaguchi A, Miyazaki Y, Ogura M, Joh K, Utsunomiya Y, Hosoya T. 2010. Glomerular density in renal biopsy specimens predicts the long-term prognosis of IgA nephropathy. Clinical Journal of the American Society of Nephrology 5(1):39–44 DOI 10.2215/CJN.04680709.

Tsuboi N, Kawamura T, Miyazaki Y, Utsunomiya Y, Hosoya T. 2011. Low glomerular density is a risk factor for progression in idiopathic membranous nephropathy. Nephrology Dialysis Transplantation 26(11):3555–3560 DOI 10.1093/ndt/gfr399.

Tsuboi N, Utsunomiya Y, Kanzagi G, Koike K, Ikegami M, Kawamura T, Hosoya T. 2012. Low glomerular density with glomerulomegaly in obesity-related glomerulopathy. Clinical Journal of the American Society of Nephrology 7(5):735–741 DOI 10.2215/CJN.07270711.

van den berg JG, van den Bergh Weerman MA, Assmann KJM, Weening JJ, Florquin S. 2004. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney International 66(5):1901–1906 DOI 10.1111/j.1523-1755.2004.00964.x.

Viggiano D, De Santo NG, Amruthraj NJ, Capolongo G, Capasso G, Anastasio P. 2019. Renal response to an oral protein load in patients with central diabetes insipidus before and after treatment with vasopressin. Journal of Nephrology 32(3):411–415 DOI 10.1007/s40620-018-00575-x.

Wang X, Vrtiska TJ, Avula RT, Walters LR, Chakkeria HA, Kremers WK, Lerman LO, Rule AD. 2014. Age, kidney function, and risk factors associate differently with cortical and medullary volumes of the kidney. Kidney International 85(3):677–685 DOI 10.1038/ki.2013.359.

Weibel ER, Gomez DM. 1962. A principle for counting tissue structures on random sections. Journal of Applied Physiology 17(2):343–348 DOI 10.1152/jappl.1962.17.2.343.